Management of complications of glucocorticoid therapy

被引:45
|
作者
Keenan, GF [1 ]
机构
[1] UNIV PENN, MED CTR, DEPT MED, PHILADELPHIA, PA 19104 USA
关键词
D O I
10.1016/S0272-5231(05)70398-1
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Cortisone was isolated from an extract of the adrenal cortex in 1935 by Mason and colleagues.(57) Cortisone synthesis was achieved in the mid-1940s. In 1948, a woman with severe rheumatoid arthritis was the first to receive cortisone.(57) By the early 1950s, glucocorticoid preparations, both oral and inhaled, had been used to treat patients with asthma. Along with recognition of the beneficial effects of this class of drugs came an increasing appreciation for their potential systemic side effects. In a trial of steroids for chronic asthma published in 1956, Christie and colleagues(22, 28) reported weight gain, hypertension, and cushingoid facies to be commonly observed side effects. In the ensuing years, the spectrum of pulmonary diseases for which corticosteroids are used has broadened, and now includes chronic obstructive pulmonary disease (COPD), sarcoidosis, pulmonary fibrosis, and the pulmonary vasculitides. Additionally, the recent success of lung transplantation has created a new population of patients requiring long-term administration of corticosteroids. Unfortunately, even with judicious use, these agents are associated with a number of side effects, some merely a nuisance but others potentially debilitating and even life-threatening. Indeed, all too commonly, steroid-induced complications may dominate the clinical course of patients with advanced lung disease. Steroid-associated complications result from altered cellular function, fluid and electrolyte shifts, modification of normal immune surveillance, and suppression of normal functioning of the adreno-pituitary axis. The occurrence of side effects is related, in part, to the method of administration, dose, and duration of use. The appearance of complications may also be of a variable and unpredictable nature, however, because of idiosyncratic responses and individual sensitivities.(25, 68, 129) Finally, some adverse effects become manifest only after the drug is tapered or withdrawn. This article discusses the more commonly encountered complications of corticosteroids in the context of the method of delivery, events occurring with chronic use, and events related to steroid withdrawal.
引用
收藏
页码:507 / +
页数:1
相关论文
共 50 条
  • [41] LEOPOLD,IH - OCULAR THERAPY - COMPLICATIONS AND MANAGEMENT
    不详
    EYE EAR NOSE AND THROAT MONTHLY, 1967, 46 (03): : 377 - &
  • [42] Complications in Device Therapy: Spectrum, Prevalence, and Management
    Llewellyn, J.
    Garner, D.
    Rao, A.
    CURRENT HEART FAILURE REPORTS, 2022, 19 (05) : 316 - 324
  • [43] Management of congenital adrenal hyperplasia: beyond conventional glucocorticoid therapy
    Khattab, Ahmed
    Marshall, Ian
    CURRENT OPINION IN PEDIATRICS, 2019, 31 (04) : 550 - 554
  • [44] Inpatient audit on management of hyperglycaemia in people on steroid (Glucocorticoid) therapy
    Hegde, P.
    Harrison, R.
    Bleasdale, V.
    Kalathil, D.
    Sharma, D.
    Purewal, T. S.
    Ahmad, A.
    Weston, P.
    Zaidi, R.
    DIABETIC MEDICINE, 2017, 34 : 174 - 175
  • [45] Eular recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases
    Jacobs, J. W. G.
    Hoes, J. N.
    Bijlsma, J. W.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 8 - 8
  • [46] Management of bone disease in patients on long term glucocorticoid therapy
    Compston, JE
    GUT, 1999, 44 (06) : 770 - 772
  • [47] Glucocorticoid therapy
    Semlacher, EA
    CANADIAN JOURNAL OF GASTROENTEROLOGY, 1997, 11 (05): : 401 - 402
  • [48] GLUCOCORTICOID THERAPY
    AXELROD, L
    MEDICINE, 1976, 55 (01) : 39 - 65
  • [49] GLUCOCORTICOID THERAPY OF NEPHRITIDES AND GLUCOCORTICOID RESISTANCE
    MUKHIN, NA
    LYASHKO, VN
    GRINBERG, KN
    TERAPEVTICHESKII ARKHIV, 1981, 53 (06) : 34 - 37
  • [50] Therapy Insight: gastrointestinal complications of diabetes—pathophysiology and management
    Joseph H Sellin
    Eugene B Chang
    Nature Clinical Practice Gastroenterology & Hepatology, 2008, 5 : 162 - 171